Clinical Trials Logo

Malignant Lymphomas clinical trials

View clinical trials related to Malignant Lymphomas.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01800630 Completed - Clinical trials for Advanced Solid Malignancies

Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

Start date: April 2013
Phase: Phase 1
Study type: Interventional

Open-label Phase 1 sequential dose-escalation study of 10 increasing doses (3 to 6 patients each)to determine and characterize the DLTs and MTD of gemcitabine HCl oral formulation (D07001-F4). Patients will be assigned to receive oral D07001-F4 on Days 1, 3, 5, 8, 10, and 12 of 4 21-day cycles each to further characterize safety and tolerability.

NCT ID: NCT01626547 Completed - Multiple Myeloma Clinical Trials

Biosimilar Retacritâ„¢ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology

Start date: December 2010
Phase: N/A
Study type: Observational

The purpose of this study is to observe correction of haemoglobin (Hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with Retacritâ„¢.

NCT ID: NCT01212341 Completed - Solid Tumors Clinical Trials

Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

MG4101
Start date: September 2010
Phase: Phase 1
Study type: Interventional

Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and expansion using an irradiated and activated autologous feeder cell system. MG4101 has anti-tumor activities against various tumors including malignant lymphomas in vitro as well as in vivo tumor model.

NCT ID: NCT01065025 Completed - Malignant Lymphomas Clinical Trials

Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies

AEGIS
Start date: January 2010
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate safety and tolerability of repeated ascending oral doses of 4SC-205 in patients with advanced and incurable solid tumors or malignant lymphomas.